Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

MLA

Dercle, Laurent, et al. “Rapid and Objective CT Scan Prognostic Scoring Identifies Metastatic Patients with Long-Term Clinical Benefit on Anti-PD-1/-L1 Therapy.” European Journal of Cancer (Oxford, England : 1990), vol. 65, Sept. 2016, pp. 33–42. EBSCOhost, https://doi.org/10.1016/j.ejca.2016.05.031.

APA

Dercle, L., Ammari, S., Champiat, S., Massard, C., Ferté, C., Taihi, L., Seban, R.-D., Aspeslagh, S., Mahjoubi, L., Kamsu-Kom, N., Robert, C., Marabelle, A., Schlumberger, M., Soria, J.-C., & Postel-Vinay, S. (2016). Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. European Journal of Cancer (Oxford, England : 1990), 65, 33–42. https://doi.org/10.1016/j.ejca.2016.05.031

Chicago

Dercle, Laurent, Samy Ammari, Stéphane Champiat, Christophe Massard, Charles Ferté, Lokmane Taihi, Romain-David Seban, et al. 2016. “Rapid and Objective CT Scan Prognostic Scoring Identifies Metastatic Patients with Long-Term Clinical Benefit on Anti-PD-1/-L1 Therapy.” European Journal of Cancer (Oxford, England : 1990) 65 (September): 33–42. doi:10.1016/j.ejca.2016.05.031.